Katholieke Universiteit te Leuven
Verified site
Leuven, Belgium
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on adults with active noninfectious intermediate, posterior, or panuveitis, a rare eye condition that causes inflammation in the middle and back parts of the eye and can lead to blurry vision or loss of sight. Participants will receive a subcutaneous injection, which means the medication is placed just under the skin, of the experimental drug tulisokibart or a matching placebo. All participants may also continue taking oral prednisone, a steroid that helps reduce inflammation, as part of their usual care.
The purpose of the study is to determine whether tulisokibart can keep the eye disease under control better than the placebo by measuring the time it takes for the disease to worsen, known as treatment failure, after the first six weeks and up to about a year later. After a screening visit, participants will be given the assigned injection at regular intervals and will attend clinic visits where doctors will check the health of the eye, note any side effects, and test visual acuity (the sharpness of vision). The study continues for several months, with safety checks throughout, and ends when the final follow‑up visit is completed.
The trial runs in 8 steps – from screening to follow-up. Each step says what happens and what the team monitors.
4 criteria
24 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Leuven, Belgium
Gent, Belgium
Brussels, Belgium
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an experimental medication being tested in this study. It is given as a subcutaneous injection using a pre‑filled injector. The drug is being evaluated to see if it can help control inflammation in the eye for people with active non‑infectious intermediate, posterior, or panuveitis. Researchers will compare how well it works to a placebo and will watch for any side effects.
is a steroid medication that is taken by mouth. In this trial, it is used as background therapy, meaning all participants continue their usual prednisone treatment while the study tests the new drug. Prednisone helps reduce eye inflammation and is part of standard care for uveitis, allowing the study to assess whether the new medication adds any extra benefit.
This medication is given as a solution for injection in a pre‑filled injector and is administered under the skin (subcutaneous injection). It is an investigational drug currently in Phase 2b clinical trials and has not yet been approved for general medical use. The drug is being tested for the treatment of noninfectious intermediate, posterior, or panuveitis, a rare inflammatory eye condition. It works by blocking specific molecules that trigger inflammation, placing it in the class of experimental anti‑inflammatory agents.
Prednisolone is taken by mouth in tablet form. It is an approved corticosteroid that has been used for many decades to treat a wide range of inflammatory and autoimmune disorders. In this study it serves as background therapy for inflammatory eye disease. The drug binds to glucocorticoid receptors, which then reduces the activity of immune cells and lowers inflammation, classifying it as a glucocorticoid steroid.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.